header logo image

SCMOM 2012_Juventas Therapeutics – Video

November 29th, 2012 6:45 am




SCMOM 2012_Juventas Therapeutics
Juventas Therapeutics is a privately held, clinical-stage biotechnology company developing factor-based regenerative therapies to treat life-threatening diseases. The company #39;s lead product, JVS-100 encodes Stromal cell-Derived Factor-1 (SDF-1) which has been shown to protect and repair tissue following ischemic injury by recruiting the body #39;s own stem cells to the damaged tissue, preventing cell death and promoting new blood vessel growth. Through activating natural stem cell based repair pathways within the patient, we eliminate the cost and complexity associated with current cellular therapies. Juventas is currently enrolling two Phase II clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients. http://www.juventasinc.com Presenter: Rahul Aras, President and CEO, Juventas TherapeuticsFrom:AllianceRegenMedViews:10 1ratingsTime:15:10More inScience Technology

Go here to see the original:
SCMOM 2012_Juventas Therapeutics - Video

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick